Vinblastina [Dcit]

Vinblastina [Dcit] Brand names, Vinblastina [Dcit] Analogs

Vinblastina [Dcit] Brand Names Mixture

No information avaliable

Vinblastina [Dcit] Chemical_Formula

C₄₆H₅₈N₄O₉

Vinblastina [Dcit] RX_link

http://www.rxlist.com/cgi/generic3/vinblastine.htm

Vinblastina [Dcit] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=29

Vinblastina [Dcit] msds (material safety sheet)

Vinblastina_[Dcit] MSDS

Vinblastina [Dcit] Synthesis Reference

No information avaliable

Vinblastina [Dcit] Molecular Weight

810.974 g/mol

Vinblastina [Dcit] Melting Point

267 ^oC

Vinblastina [Dcit] H₂O Solubility

Negligible

Vinblastina [Dcit] State

Solid

Vinblastina [Dcit] LogP

5.587

Vinblastina [Dcit] Dosage Forms

Liquid; Powder for solution; Solution

Vinblastina [Dcit] Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Vinblastina [Dcit] Pharmacology

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Vinblastina [Dcit] Absorption